Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD)....
+See More2018-12-05 09:38:00 Wednesday ET
Federal Reserve publishes its inaugural flagship financial stability report. Fed Chair Jerome Powell applauds both low inflation (2%) and low unemployment (
2019-01-06 08:39:00 Sunday ET
President Trump signs an executive order to freeze federal employee pay in early-2019. Federal employees face furlough or work without pay due to the govern
2019-12-22 08:30:00 Sunday ET
European Commission President Ursula von der Leyen now protects the European circular economy and green growth from 2020 to 2050. The new circular economy r
2017-09-19 05:34:00 Tuesday ET
Facebook, Twitter, and Google executives head before the Senate Judiciary Committee to explain the scope of Russian interference in the U.S. presidential el
2018-10-15 09:33:00 Monday ET
Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an
2019-11-15 13:34:00 Friday ET
The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and go